Progressive multifocal leukoencephalopathy

A 25-year retrospective cohort study

Pria Anand, MD, Gladia C. Hotan, BS, Andre Vogel, BA, Nagagopal Venna, MD, and Farrah J. Mateen, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2019;6:e618. doi:10.1212/NXI.0000000000000618

Correspondence

Dr. Anand
pria.anand@gmail.com

Abstract

Objective

To characterize the risk factors, clinical course, and treatment of patients with progressive multifocal leukoencephalopathy (PML) diagnosed and followed over a 25-year epoch at 2 academic hospitals.

Methods

Patients with a definite diagnosis of PML were identified by positive CSF PCR for JC virus or histopathology between January 1, 1994, and January 1, 2019. Demographic and PML-specific variables were recorded on symptomatic presentation and at follow-up, including risk factors, clinical outcome, neuroimaging findings, and modified Rankin Scale (mRS) score at last follow-up.

Results

There were 91 patients with confirmed PML. HIV infection was the most common risk factor, identified in 49% ($n = 45$). Other frequent risk factors included lymphoma, leukemia, or myelodysplasia, identified in 31% of patients ($n = 28$); exposure to chemotherapeutic medications (30%, $n = 27$); and exposure to monoclonal antibody therapies (19%, $n = 17$). Thirty percent of the cohort was alive at the time of censoring, with a median mRS of 2 points, indicating slight disability at last follow-up. Median survival following PML diagnosis in HIV-infected patients was longer than in HIV-uninfected patients (1,992 vs 101 days, $p = 0.024$). Forty patients survived more than 1 year after PML symptom onset, of whom 24 were HIV infected (60%). Thirteen patients survived more than 10 years after PML symptom onset, all HIV infected, of the 59 patients diagnosed before June 1, 2009, and eligible for 10-year survivor status (22%).

Conclusions

We add to the limited literature on PML by reporting its epidemiology in a large observational cohort. These parameters may be useful for future clinical trials that measure survival and clinical outcomes.

From the Department of Neurology (P.A., A.V., N.V., F.J.M.), Massachusetts General Hospital, Boston; and Department of Brain and Cognitive Sciences (G.C.H.), Massachusetts Institute of Technology, Cambridge.

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

AAN = American Academy of Neurology; cART = combined antiretroviral therapy; IRIS = immune reconstitution inflammatory syndrome; mRS = modified Rankin Scale; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting MS.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the CNS caused by reactivation of JC virus leading to oligodendrocyte destruction. Similar to other human polyoma viruses, JC virus is an opportunistic pathogen, with PML manifesting primarily in patients with innate immunodeficiency or taking immunomodulatory medications. The pathology of PML was first reported in 1958 in a patient with chronic lymphocytic lymphoma.¹ By 1982, the syndrome had been characterized in HIV-infected patients.² In 2005, PML was first reported in patients treated with natalizumab, a monoclonal antibody approved by the Food and Drug Administration to treat relapsing-remitting MS (RRMS).^{3,4}

PML has been reported in association with rheumatologic diseases, lymphoreticular malignancies, and post-organ transplantation immunosuppression, and less frequently, in cases without recognized immunosuppression. As new immunosuppressive therapies are introduced and used increasingly broadly across disease states, PML has been described in association with rituximab, cyclophosphamide, methotrexate, mycophenolate mofetil, dimethyl fumarate, fingolimod, and cyclosporine.^{5–7}

Treatment options for PML are limited. Withdrawal of immunosuppressive medications and, in the case of HIV-infected individuals, provision of antiretroviral therapy offer the only clear survival benefit.⁸ Previous studies have explored the efficacy of 5-hydroxytryptamine antagonists including mirtazapine and risperidone, nucleoside analogs including cidofovir and cytosine arabinoside, and biological therapies including interferon alpha, without proven efficacy.^{9–12} More recently, favorable outcomes have been reported in patients treated with immune checkpoint inhibitor therapy^{13–15} and infusion of virus-specific T cells.¹⁶

Although large cohorts of patients with PML in the setting of natalizumab have been described,^{17,18} most of the literature on diverse etiologies of PML in recent decades has been limited to small case series and individual reports, which are subject to publication bias based on either unexpectedly favorable or unfavorable outcomes.^{19,20} With the new promise of effective therapy for this devastating disease, understanding the diverse presentations of PML is increasingly important because early manifestations may be difficult to recognize but are most amenable to treatment. Here, we report the risk factors and outcomes in a cohort of patients diagnosed with PML and followed at 2 tertiary care hospitals in the United States over a 25-year period.

Methods

Ethics

The study protocol was approved by the Partners Healthcare Institutional Review Board of Massachusetts General Hospital.

Patient identification

Patients were identified by searching the Partners Health Care Research Patient Data Registry system using the *International Classification of Diseases 9th and 10th edition* diagnostic codes for PML (046.3, A81.2). All patients who were diagnosed with PML and presented to Massachusetts General Hospital or Brigham and Women's Hospital between January 1, 1994, and January 1, 2019, were included on initial review (figure 1). These dates were chosen based on the initiation of electronic medical records at the study's hospitals.

Diagnostic criteria

Patients with a definite diagnosis of PML were identified using diagnostic criteria previously published by the American Academy of Neurology (AAN).²¹ For patients with available histopathology, this included the presence of demyelination, bizarre astrocytes, enlarged oligodendroglial nuclei, and either positive tissue PCR for JC virus, positive immunohistochemistry, or visualization of viral particles using electron microscopy. For patients without histopathology, this included the presence of compatible clinical features, compatible radiologic findings, and a positive CSF PCR for JC virus. Patients whose available medical records were limited to histopathology results without clinical data were excluded from analysis. All included patients were diagnosed and treated by a neurologist before the authors' electronic medical records review.

Data collection and variables

Data on the initial clinical presentation and follow-up, until a censoring date of June 1, 2019, were collected in a central database. Variables of interest included sex, date of birth, clinical outcome, date of PML-related symptom onset, date of PML diagnosis, HIV infection status, malignancy status, transplantation status, immunosuppressive medications, CSF profile, JC virus positivity in serum and CSF, JC virus copy number or index value, and PML treatment modalities pursued. Previously published clinical diagnostic criteria were used to identify patients who developed immune reconstitution inflammatory syndrome (IRIS).²² For patients who were HIV infected, CD4 count and HIV viral load at the time of PML diagnosis were included. Presenting symptoms were reviewed and categorized.

Figure 1 Flowchart describing the selection of this cohort

The first brain MRI obtained for each patient after the onset of symptoms were reviewed by a study neurologist (P.A.) and coded with respect to multifocality, presence or absence of gadolinium enhancement, and the anatomic location of lesions. Histopathology reports obtained through brain biopsy or autopsy were reviewed and coded with respect to the presence or absence of demyelination, bizarre astrocytes, enlarged oligodendroglial nuclei, tissue PCR, immunohistochemistry, and visualization of viral particles using electron microscopy. All treatments administered for PML were recorded for each patient.

For patients for whom a date of death was not recorded, a search of the US Social Security Administration Death Master File and the Massachusetts Registry of Vital Records and Statistics was performed to determine the date of death. For patients who remained alive as of April 1, 2019, a modified Rankin Scale (mRS) score was calculated at the last clinical follow-up. Patients who had last been seen by a neurologist more than 1 year earlier had an mRS determined through a telephone assessment. Patients who were diagnosed with PML on June 1, 2009, or earlier were eligible to be 10-year survivors in this study.

Statistical analysis

All analyses were completed using Microsoft ExcelTM and Python 2.7.14. Patient characteristics were summarized by expressing categorical variables as counts and proportions and continuous variables as medians. Major risk factors for PML were studied for prevalence in 5-year epochs, beginning with the study observation period's first observed time point on January 1, 1994, and counted as every 5 years afterward.

Patients with HIV infection were compared with all those without HIV infection using the 2-proportion z-test for differences in proportions, the unequal variance *t*-test for differences in means, and the Kruskal-Wallis test for differences in medians.

A Kaplan-Meier estimator was used to graph the survival of patients from the time of PML diagnosis to either death or the date of last known follow-up. The median survival was compared between HIV-infected and non-HIV-infected patients using a log-rank test. A *p* value of 0.05 or less was considered statistically significant.

Data availability

Data will be made available upon reasonable request by qualified investigators and subject to ethics board approvals.

Results

Patient characteristics

There were 91 patients (*n* = 53, 58% male) with confirmed PML with a median age at symptomatic onset of 53 years (range 24–80 years) (table 1). HIV-infected PML patients were younger at the time of symptomatic onset, with a median age of 42 years compared with 67 years in HIV-uninfected patients (*p* < 0.001). HIV-infected patients were more often male (71%, *n* = 32) compared with HIV-uninfected patients (46%, *n* = 21) (*p* = 0.014). The most common presenting symptoms observed were hemiparesis and gait and speech abnormalities.

The median time between symptomatic onset and diagnosis of PML was 40 days, with a minimum time of 5 days and a maximum time of 2 years, the latter in a patient with

Table 1 Cohort characteristics, January 1, 1994, to January 1, 2019 (n = 91)

Cohort characteristics (n = 91)	n	%
Male	53	58
Age at onset of PML symptoms (y)		
20–30	6	7
31–40	15	16
41–50	20	22
51–60	14	15
61–70	24	26
71–80	12	13
Status at last follow-up		
Deceased	63	69
Alive	27	30
Median mRS at last follow-up	2	
Lost to follow-up	1	1
Risk factors for PML ^a		
HIV infection	45	49
Median CD4 cell count at diagnosis	106 cells/mL	
Median plasma HIV viral load at diagnosis	72,500 copies/mL	
Chemotherapy ^b	27	30
Lymphoma, leukemia, or myelodysplasia	28	31
Bone marrow or stem cell transplant	3	3
Monoclonal antibody ^c	17	19
MS disease-modifying drug ^d	4	4
Other innate immunodeficiency ^e	7	8
Rheumatologic disease ^f	8	9
Rheumatologic disease-modifying drug ^g	8	9
Carcinoma	6	7
Solid organ transplant	3	3
Splenectomy	2	2
Presenting symptoms ^a		
Aphasia	13	14
Apraxia	4	4
Diminished level of consciousness	1	1
Dysarthria	17	19
Dysmetria	15	16
Gait instability	23	25
Headache	4	4
Hemiparesis	28	31

Table 1 Cohort characteristics, January 1, 1994, to January 1, 2019 (n = 91) (*continued*)

Cohort characteristics (n = 91)	n	%
Memory impairment	11	12
Neglect	2	2
Psychiatric symptoms	2	2
Seizure	8	9
Sensory symptoms	5	5
Tremor	2	2
Vertigo	9	10
Vision changes	11	12
MRI findings ^a		
Multifocality of lesions	65	71
Posterior fossa involvement	41	45
Enhancement with gadolinium	25	27
Mass effect	6	7
Method of diagnosis ^a		
CSF JC virus PCR	71	78
Histopathologic triad	32	35

Abbreviations: mRS = modified Rankin Scale; PML = progressive multifocal leukoencephalopathy.

^a Patients may fall into multiple categories.

^b Includes busulfan, bendamustine, cyclophosphamide, doxorubicin, and fludarabine.

^c Includes brentuximab, rituximab, ofatumumab, and alemtuzumab.

^d Includes dimethyl fumarate and natalizumab.

^e Includes common variable immunodeficiency, cytopenias, and hypogammaglobulinemia.

^f Includes sarcoidosis, granulomatous polyangiitis, systemic lupus erythematosus, and rheumatoid arthritis.

^g Includes adalimumab, plaquenil, mycophenolate mofetil, corticosteroids, azathioprine, and methotrexate.

idiopathic lymphopenia. Time to diagnosis was shorter in HIV-infected patients vs HIV-uninfected patients, but this was not statistically significant (32 vs 48 days, $p = 0.199$). Among patients with lymphoma, leukemia, or myelodysplasia, the median time to diagnosis was 48 days. Seventeen patients had a JC viral copy number tested in CSF at the time of PML diagnosis, with a median of 2,430 copies.

PML risk factors

The major predisposing factors for PML are reported in table 1, with risk factors categorized by 5-year epoch reported in table 2. HIV infection was the most common risk factor, identified in 49% of the 91 patients. Other frequent risk factors included lymphoma, leukemia, or myelodysplasia, identified in 31% of patients ($n = 28$), exposure to chemotherapeutic medications (30%, $n = 27$), and exposure to monoclonal antibody therapies (19%, $n = 17$). Several patients had exposure to multiple risk factors; for instance, 20 patients with lymphoma, leukemia, or myelodysplasia were

Table 2 Number of patients affected by various risk factors for progressive multifocal leukoencephalopathy, separated based on year of progressive multifocal leukoencephalopathy symptom onset

Risk factor ^a	1994–1998 (n = 9)	1999–2003 (n = 14)	2004–2008 (n = 32)	2009–2013 (n = 11)	2014–2018 (n = 25)
HIV infection	6	9	18	5	7
Rheumatologic disease	0	0	1	0	7
Lymphoma, leukemia, or myelodysplasia	3	3	11	3	8
Splenectomy	0	0	2	0	0
Carcinoma	0	0	4	0	2
Bone marrow or stem cell transplant	0	1	0	0	2
Solid organ transplant	0	1	0	0	2
Other innate immunodeficiency	0	0	3	1	3
MS disease-modifying drug	0	0	0	1	3
Monoclonal antibody	0	1	7	3	6
Chemotherapy	3	3	12	3	6
Rheumatologic disease-modifying drug	0	0	1	0	7

^a Patients may have been exposed to multiple risk factors.

also exposed to chemotherapeutic medications, 3 had bone marrow or stem cell transplants, and 1 had comorbid HIV infection. Eight patients had underlying rheumatologic diseases, including sarcoidosis, granulomatous polyangiitis, systemic lupus erythematosus, and rheumatoid arthritis. All these patients were treated with disease-modifying therapies, including adalimumab, plaquenil, mycophenolate mofetil, corticosteroids, azathioprine, and/or methotrexate. One patient, diagnosed in 2002 and deceased 2 months later, had no known risk factors at the time of PML symptom onset; however, extensive immunologic and hematologic evaluations were not undertaken in this patient.

Among the 3 patients with solid organ transplants, 1 had undergone a double-lung transplant 4 years before the onset of PML symptoms, followed by a combined double-lung and kidney transplant 2 months before symptom onset for cystic fibrosis; 1 had undergone a single kidney transplant 19 years before symptom onset and was awaiting a liver transplant for hepatorenal syndrome secondary to alcoholic cirrhosis; and 1 had undergone an orthotopic heart transplant for nonischemic cardiomyopathy 2 years before the onset of symptoms.

Among the 3 patients with bone marrow and stem cell transplants, 1 had undergone a stem cell transplant 10 years before the onset of PML symptoms for chronic lymphocytic leukemia, followed by treatment with cyclophosphamide, vincristine, prednisone, and fludarabine for recurrent leukemia beginning 2 years before symptom onset complicated by pancytopenia; 1 had undergone a bone marrow transplant for

non-Hodgkin lymphoma 2 years before symptom onset, followed by treatment with cyclophosphamide, rituximab, and radiation 1 year before symptom onset; and 1 had undergone autologous stem cell transplant 4 years before symptom onset and allogeneic stem cell transplant for relapsed disease 2 years before symptom onset, followed by therapy with rituximab and brentuximab for graft vs host disease beginning 3 months before symptom onset.

Four patients with a diagnosis of RRMS were included in the cohort. One patient had been treated with dimethyl fumarate since diagnosis with RRMS 3 years before the onset of PML symptoms. Three patients were treated with natalizumab. One patient had been on natalizumab for 3 years before the onset of PML symptoms and had previously been treated with interferon beta-1a and glatiramer acetate; 1 patient had been on natalizumab for 8 years before symptom onset and had been previously treated with interferon beta-1b and glatiramer acetate; and 1 patient had been on natalizumab for 1 year before symptom onset and had previously been treated with interferon beta-1a and glatiramer acetate. All 4 patients with RRMS were alive as of the censoring date, with durations of follow-up between 4 and 7 years. Three presented with new neurologic symptoms, including dysarthria, dysmetria, gait instability, headache, and visual changes. One was asymptomatic and was evaluated for PML because of changes seen on a surveillance brain MRI.

Survival analysis

Vital status could not be ascertained in 1 patient, who was excluded from the analysis of final outcomes. Thirty percent of

the cohort was alive at the time of censoring (27/90), with a median mRS of 2 points (slight disability) at last follow-up. Eight patients had an mRS of 0 points (no symptoms, 30%), 5 had an mRS of 1 point (no significant disability, 19%), 6 had an mRS of 2 points (slight disability, 22%), 1 had an mRS of 3 points (moderate disability, 4%), 4 had an mRS of 4 points (moderately severe disability, 15%), and 3 had an mRS of 5 points (severe disability, 11%). One patient was diagnosed on the day of death. Median survival following PML was longer in patients who were HIV-infected patients (1,992 days) compared with patients who were HIV uninfected (101 days, $p = 0.024$) (figure 2).

Forty patients survived more than 1 year after the onset of PML symptoms, of whom 24 were HIV infected (60%). Thirty-three of 45 HIV-infected patients (73%) and 24/46 HIV-uninfected patients (52%) were diagnosed before June 1, 2009, and eligible for 10-year survivor status. Thirteen of 59 eligible patients survived more than 10 years after PML symptom onset (22%). Ten-year survivors were all HIV infected, with either a new diagnosis of HIV at the time of PML diagnosis or nonadherence with previously prescribed combined antiretroviral therapy (cART) (table 3). Five 10-year survivors were diagnosed with PML-IRIS following the PML diagnosis. Follow-up brain imaging in 10-year survivors predominantly revealed brain volume loss in areas that were previously involved by PML on initial imaging (figure 3). In addition to 10-year survivors, 2 patients survived for more

than 5 years after the onset of symptoms; 1 was HIV infected, and 1 had RRMS and exposure to natalizumab. No PML disease relapses were noted in any PML survivors.

PML-directed treatment

All HIV-infected patients were started on cART following PML diagnosis ($n = 46$). Thirty-seven percent ($n = 34$) of patients were treated with mirtazapine, and 15% ($n = 14$) were treated with mefloquine (table 4). Other therapies used in the treatment of PML included adoptive T-cell therapy, checkpoint inhibitor therapy, cidofovir, cytosine arabinoside, interferon alpha-2A, interleukin-2 inhibitor, IV immunoglobulins, and plasmapheresis. All 10-year survivors of PML were initiated on cART, and 1 was treated with cytosine arabinoside. No other PML-directed therapies were used in the treatment of patients who survived 10 or more years after PML symptom onset.

Discussion

Epidemiologic studies of PML remain rare despite the widespread awareness of the condition. Our findings demonstrate that, as PML is seen less often in HIV-infected individuals, new and repurposed immunosuppressive medications are increasingly recognized as predisposing factors for PML. Much attention has been focused in recent years on specific PML risk factors, including HIV infection and the use of natalizumab therapy in patients with RRMS. Although our study is not

Figure 2 The Kaplan-Meier estimator demonstrating survival following progressive multifocal leukoencephalopathy diagnosis in HIV-infected and HIV-uninfected patients^{a,b}

Table 3 Characteristics of patients who survived 10 or more years after the onset of PML symptoms^a

Patient	Sex, decade of life	CD4 count at PML diagnosis (cells/mm ³)	Viral load at PML diagnosis (copies/mL)	Duration of follow-up after PML diagnosis (y)	mRS at last follow-up	cART administered	HIV status at the time of PML diagnosis ^b	PML-IRIS or not	PML-directed therapy
1	M, second	90	78,000	14	1	EFV, FTC, TDF	N	Y	N
2	F, fourth	43	Unavailable	11	6	RTV, ddi	A	N	N
3	M, fifth	130	Unavailable	20	6	ZDV, ddi	A	N	Cytosine arabinoside
4	M, third	36	750,000	18	0	d4T, 3TC, ABC, NVP	A	N	N
5	M, fourth	103	421,000	17	2	ZDV, 3TC, NFV	N	Y	N
6	M, fourth	241	153,000	17	1	ZDV, 3TC, EFV	A	N	N
7	F, third	20	182,000	15	0	ZDV, 3TC, RTV, LPV	N	N	N
8	M, fourth	71	500,000	15	0	RTV, ATV, TAF	A	N	N
9	F, third	493	Unavailable	14	2	NVP, FTC, TDF	A	Y	N
10	F, third	243	Undetectable	14	4	FTC, ATV, RTV, TDF	A	N	N
11	M, fourth	190	40,700	13	0	LPV, RTV, 3TC, ZDV	N	N	N
12	M, fifth	130	803,000	12	2	ATV, TDF, FTC	A	Y	N
13	M, fifth	108	81	12	4	LPV, RTV, FTC, TDF	N	Y	N

Abbreviations: 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; cART = combined antiretroviral therapy; d4T = stavudine; ddi = didanosine; EFV = efavirenz; FTC = emtricitabine; IRIS = immune reconstitution inflammatory syndrome; LPV = lopinavir; mRS = modified Rankin Scale; NFV = nelfinavir; NVP = nevirapine; PML = progressive multifocal leukoencephalopathy; RTV = ritonavir; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine.

^a All 10-year survivors were HIV infected.

^b N = new diagnosis of HIV at the time of PML diagnosis, A = known HIV, nonadherent with cART at the time of PML diagnosis.

population based and does not report on incidence, we provide granular clinical data from 2 large academic tertiary care hospitals to elucidate the etiologies and outcomes for PML patients. We show here that despite previous interest in single medications or disease processes, PML occurs due to a broad range of risk factors that are often multiple and overlapping. This includes patients who both have underlying risk such as malignancy or rheumatologic disease and are exposed to 1 or more immunosuppressive medications.

Previous large cohort studies have focused on HIV infection as a predisposing risk factor for PML and have shown a decrease in the incidence of PML in HIV-infected patients with the advent of cART. In the pre-cART era, 1 study of 79 HIV-infected patients diagnosed between 1979 and 1983 at a single center found that 3.8% had PML.²³ A Danish cohort of 47 HIV-infected patients with PML identified during the pre-cART (1995–1996), early cART (1997–1999), and late cART (2000–2006) periods found that although the incidence of

PML in HIV-infected patients had decreased, survival remained poor, with a median duration of 146 days.²⁴ A prospective French study of 92,477 HIV-infected patients followed between 1997 and 2011 found that 555 developed PML, with a decrease in incidence of 57% over the 15-year study period.²⁵ The Swiss HIV cohort followed 186 HIV-infected patients with PML and found a decrease in PML incidence and mortality associated with cART independent of baseline CD4 T-cell count.²⁶ Here, we find that the median survival following PML in HIV-infected patients is longer than in HIV-uninfected patients (1,992 vs 101 days, $p = 0.024$). The most common presenting symptoms in our cohort, hemiparesis and gait and speech abnormalities, reflect those described in the largest HIV-PML cohort described in the literature.²

Limited literature exists on longer-term survivors of PML. A 2010 study described the clinical outcome of 24 patients with PML whose survival exceeded 5 years, demonstrating that the majority of survivors improved or were stable in their deficits

Figure 3 MRI in 4 of 13 patients who survived 10 or more years after the onset of PML symptoms

Case 1: A 37-year-old HIV-infected woman was nonadherent with her combined antiretroviral therapy for 2 years and presented with dysarthria and left hand clumsiness. (A) T2-weighted fluid attenuation inversion recovery (FLAIR) sequences revealed a large zone of hyperintensity involving the right frontal lobe, extending into the deep white matter and sparing the cortical ribbon. (B) Follow-up MRI 12 years later demonstrated tissue loss involving the right frontal lobe with associated ex vacuo dilatation of the frontal horn of the right lateral ventricle. Case 2: a 39-year-old HIV-infected man presented with gait ataxia and falls. (C) MRI revealed T2-FLAIR hyperintensity predominantly involving the left cerebellar hemisphere. (D) Follow-up MRI 12 years later demonstrated severe cerebellar and brainstem volume loss. Case 3: a 48-year-old injection drug user presented with behavioral changes, seizures, and aphasia and was found to be HIV infected. (E) MRI revealed multifocal areas of subcortical T2/FLAIR hyperintensity. (F) Follow-up MRI 10 years later revealed asymmetric volume loss. PML = progressive multifocal leukoencephalopathy.

after 5 years from onset of symptoms.²⁷ As in our study, the majority of long-term survivors of PML were found to be HIV infected. Here, we report on the outcomes of thirteen 10-year survivors of PML out of 59 patients who were followed for 10 or more years after the onset of symptoms, including 1 patient

followed at our center for >18 years. We have performed nearly a complete case analysis, with only 1 patient lost to follow-up, allowing for robust estimates of survival and functional outcome among survivors. All the 10-year PML survivors in our study were HIV infected, with 1 patient with RRMS who survived for

Table 4 PML-directed therapies administered to the cohort

PML-directed therapy administered ^a	Number treated	Number alive at censoring date	Dosing and administration
Adoptive T-cell therapy	1	1	Single IV transfusion
Cidofovir	8	2	5 mg/kg IV weekly for 2 wk, then biweekly
Cytosine arabinoside	2	0	4 mg/kg IV for 4–5 d
Immunoglobulins	9	2	300–2,000 mg/kg every 3–4 wk
Interleukin-2 inhibitor	3	0	1 million units SQ once, followed by 1.8 million unit SQ daily
Mefloquine	14	5	250 mg orally daily for 3 d, then weekly
Mirtazapine	34	11	15–45 mg orally given nightly
Peginterferon alpha-2A	3	0	180 µg SQ weekly
Pembrolizumab	2	0	2 mg/kg IV given every 4–6 wk
Plasmapheresis	2	1	Every other day for 5 sessions

Abbreviations: PML = progressive multifocal leukoencephalopathy; SQ = subcutaneously.

^a Patients may have received multiple therapies.

more than 5 years following natalizumab-induced PML. As a more positive finding, the majority of PML survivors in our cohort had either no or slight disability at the time of follow-up, suggesting that those who survive can anticipate functional independence in most cases. These findings may help to inform prognostication in future cases of PML. Although multiple therapeutic options have been offered in the treatment of PML, all the 10-year survivors in our cohort were treated with cART, and just 1 received another PML-directed therapy.

We also identify a diagnostic delay, with a median time to diagnosis of 40 days. This finding replicates earlier studies demonstrating frequent misdiagnosis of PML, including a retrospective Swedish national study from 1988 to 2013.²⁸ A separate Boston-based retrospective study at a different institution covering the years 1993–2015 reported a median time from initial PML symptom onset to PML diagnosis of 74 days.²⁹ In nearly two-thirds of patients, a different diagnosis was first considered. Our cohort included a patient with unexplained lymphopenia who was diagnosed with PML 2 years after the initial onset of symptoms. In an era of available PML-directed therapy, this delay may affect clinical outcomes.

In part, this delay may be fueled by stringent criteria for a diagnosis of PML. A Dutch-Belgian cohort of 28 patients with PML found that 18 patients met the AAN criteria²¹ for high diagnostic certainty for PML at initial evaluation, which increased to 20 patients on follow-up evaluation.³⁰ The remainder of the cohort was classified as either “possible PML” or “not PML” despite a very high suspicion for PML based on MRI characteristics. A second study of 128 patients with PML in the setting of natalizumab exposure found that JC virus detection in CSF had a poor sensitivity for the diagnosis of early PML.³¹ Earlier proposed criteria were formulated for patients

with exposures to specific risk factors.³² These failed to account for exposures to a diverse profile of overlapping risk factors.

Our study is limited by its retrospective nature. It is also subject to referral bias. In particular, the hospitals included in this analysis are both tertiary care centers and may be enriched for an oncologic population, as well as for less common underlying risk factors and exposures. Our study did not include city- or state-wide data and did not capture data from the public hospitals in the region. Both hospitals primarily care for adult patients, and our data collection expectedly captured no pediatric cases. Although PML is rarely seen in children, pediatric cases are described in the literature.³³ Our cases were subject to strict selection criteria: the requirement for CSF JC virus PCR positivity or histopathology to make a definitive diagnosis of PML. These criteria may have selected for more severe cases that proceeded to lumbar puncture or brain biopsy. Although this provides a high level of confidence in the accuracy of the diagnosis in included cases, our use of stringent criteria almost certainly underestimated the number of PML cases by eliminating cases that were based on neuroimaging findings alone. Finally, because we used a variety of sources to ascertain vital status at the censoring date, we are unable to comment on cause of death in our patient population. Patients who died with PML may not have died because of PML in all cases, particularly given the independent contribution of underlying risk factors.

Unlike other recent studies that result from drug safety programs or disease-specific entities, our work includes the range of risk profiles for PML in a large, academic, US setting. This adds to the limited literature comprising PML cohorts with large sample sizes. Survival following PML remains short for most patients at less than 2 months. However, long-term survivorship is possible in those with HIV infection and initiation

of cART. Although we cannot conclude that any specific cART regimen was definitely effective for long-term survival, we present the regimens that have been successfully used at our center for patients with HIV-PML who survived 10 or more years after the onset of PML symptoms. We provide observational, retrospective data on a range of other attempted therapies in our patients for other researchers to include and synthesize across centers in future studies. Finally, our study offers a historical comparison for treatment cohorts as promising PML therapies enter into clinical trials.^{13–16}

Study funding

No dedicated study funding.

Disclosure

P. Anand, G.C. Hotan, A. Vogel, and N. Venna report no disclosures. F.J. Mateen has consulted for Genentech Roche and Oxford Pharmagenesis, unrelated to the present work. Go to Neurology.org/NN for full disclosures.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* July 3, 2019. Accepted in final form August 13, 2019.

Appendix Authors

Name	Location	Role	Contribution
Pria Anand, MD	Massachusetts General Hospital, Boston	Author	Design and conceptualization of the study; collection and analysis of data; and drafted the manuscript for intellectual content
Gladia C. Hotan, BS	Massachusetts Institute of Technology, Cambridge	Author	Analysis and interpretation of data and revision of the manuscript for intellectual content
Andre Vogel, BA	Massachusetts General Hospital, Boston	Author	Acquisition of data and revision of the manuscript for intellectual content
Nagagopal Venna, MD	Massachusetts General Hospital, Boston	Author	Acquisition of data and revision of the manuscript for intellectual content
Farrah J. Mateen, MD, PhD	Massachusetts General Hospital, Boston	Author	Design and conceptualization of the study; analysis of data; revision of the manuscript for intellectual content; and study supervision

References

1. Åström KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease. *Brain* 1958;doi:10.1093/brain/81.1.93.
2. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. *J Neurovirol* 1998;4:59–68. doi:10.3109/13550289809113482.
3. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N Engl J Med* 2005;353:375–381. doi:10.1056/nejmoa051847.
4. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. *N Engl J Med* 2005;353:369–374. doi:10.1056/nejmoa051782.

5. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. *Arch Neurol* 2011;68:1156–1164. doi:10.1001/archneurol.2011.103.
6. Calabrese LH, Molloy ES. Progressive multifocal leukoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. *Ann Rheum Dis* 2008;67(3 suppl):iii64–iii65. doi:10.1136/ard.2008.097972.
7. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. *Ann Neurol* 2009;65:367–377. doi:10.1002/ana.21630.
8. Aksamit AJ. Progressive multifocal leukoencephalopathy. *Contin Lifelong Learn Neurol* 2013. doi:10.1212/01.con.0000423852.70641.de.
9. Owczarczyk K, Hilker R, Brunn A, Hallek M, Rubbert A. Progressive multifocal leukoencephalopathy in a patient with sarcoidosis—successful treatment with cidofovir and mirtazapine. *Rheumatology (Oxford)* 2007;46:888–890. doi:10.1093/rheumatology/kem049.
10. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. *Mayo Clin Proc* 2001;76:1171–1175. doi:10.4065/76.11.1171.
11. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. *AIDS Clinical Trials Group 243 Team. N Engl J Med* 1998;338:1345–1351.
12. Skromne E, Rivera VM, Ontaneda D, Ordonez L. Progression of progressive multifocal leukoencephalopathy despite treatment with β -interferon. *Neurology* 2006;66:1787–1788. doi:10.1212/01.wnl.0000230563.29202.6a.
13. Walter O, Treiner E, Bonneville F, et al. Treatment of progressive multifocal leukoencephalopathy with nivolumab. *N Engl J Med* 2019;380:1674–1676. doi:10.1056/NEJMc1816198.
14. Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. *N Engl J Med* 2019;380:1597–1605. doi:10.1056/NEJMoA1815039.
15. Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB. Progressive multifocal leukoencephalopathy treated with nivolumab. *J Neurovirol* 2019;25:284–287. doi:10.1007/s13365-019-00738-x.
16. Rezvani K, Marin D. Allogeneic BK virus-specific T cells for PML. *N Engl J Med* 2019;380:106. doi:10.1056/nejmc1815050.
17. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. *N Engl J Med* 2012;366:1870–1880. doi:10.1056/NEJMoA1107829.
18. Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. *Neurology* 2017;88:1144–1152. doi:10.1212/WNL.0000000000003740.
19. Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, et al. Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: a case report. *J Oncol Pharm Pract* 2019;25:998–1002. doi:10.1177/1078155218769367.
20. Rastogi A, Gulati N, Bihari C, et al. JC virus-related progressive multifocal leukoencephalopathy after living-donor liver transplant: a rare case. *Exp Clin Transpl* 2017;17:414–417. doi:10.6002/ect.2016.0242.
21. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. *Neurology* 2013;80:1430–1438.
22. McCarthy M, Nath A. Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS). *Curr Neurol Neurosci Rep* 2010;10:467–475. doi:10.1007/s11910-010-0138-y.
23. Krupp LB, Lipton RB, Swerdlow ML, Leeds NE, Llena J. Progressive multifocal leukoencephalopathy: clinical and radiographic features. *Ann Neurol* 1985;17:344–349. doi:10.1002/ana.410170407.
24. Engsig FN, Hansen A-BE, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. *J Infect Dis* 2009;199:77–83. doi:10.1086/595299.
25. Melliez H, Mary-Krause M, Bocket L, et al. Risk of progressive multifocal leukoencephalopathy in the combination antiretroviral therapy era in the French hospital database on human immunodeficiency virus (ANRS-C4). *Clin Infect Dis* 2018;67:275–282.
26. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV cohort study. *Clin Infect Dis* 2009;48:1459–1466. doi:10.1086/598335.
27. Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. *J Neurol Neurosurg Psychiatry* 2010;81:1288–1291. doi:10.1136/jnnp.2009.179002.
28. Iacobaeus E, Burkill S, Bahmanyar S, et al. The National incidence of PML in Sweden, 1988–2013. *Neurology* 2018;90:e498–e506. doi:10.1212/WNL.0000000000004926.LK.
29. Miskin DP, Ngo LH, Koralnik IJ. Diagnostic delay in progressive multifocal leukoencephalopathy. *Ann Clin Transl Neurol* 2016;3:386–391.
30. Wijburg MT, Warnke C, Barkhof F, Uitendaele BMJ, Killestein J, Wattjes MP. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. *J Neurol Neurosurg Psychiatry* 2019;90:44–46.
31. Blankenbach K, Schwab N, Hofner B, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. *Neurology* 2019;92:e2232–e2239. doi:10.1212/WNL.0000000000007451.
32. Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. *J Neurol Neurosurg Psychiatry* 2012;83:927–933. doi:10.1136/jnnp-2012-302478.
33. Berger JR, Scott G, Albrecht J, Belman AL, Tornatore C, Major EO. Progressive multifocal leukoencephalopathy in HIV-1-infected children. *AIDS* 1992;6:837–841. doi:10.1097/00002030-199208000-00012.

Neurology® Neuroimmunology & Neuroinflammation

Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study

Pria Anand, Gladia C. Hotan, Andre Vogel, et al.

Neurol Neuroimmunol Neuroinflamm 2019;6;

DOI 10.1212/NXI.0000000000000618

This information is current as of September 25, 2019

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/6/6/e618.full.html
References	This article cites 31 articles, 4 of which you can access for free at: http://nn.neurology.org/content/6/6/e618.full.html##ref-list-1
Citations	This article has been cited by 3 HighWire-hosted articles: http://nn.neurology.org/content/6/6/e618.full.html##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): HIV http://nn.neurology.org/cgi/collection/hiv Multiple sclerosis http://nn.neurology.org/cgi/collection/multiple_sclerosis
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.